Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$116K Buy
899
+203
+29% +$23.8K 0.01% 94
2026
Q1
$83.7K Buy
696
+5
+0.7% +$577 0.01% 103
2025
Q4
$72.7K Buy
691
+32
+5% +$3K 0.01% 108
2025
Q3
$55.3K Buy
659
+23
+4% +$1.89K 0.01% 109
2025
Q2
$50.4K Buy
636
+6
+1% +$477 0.01% 113
2025
Q1
$56.6K Buy
630
+5
+0.8% +$467 0.01% 104
2024
Q4
$62.2K Buy
625
+4
+0.6% +$412 0.01% 103
2024
Q3
$70.5K Buy
621
+4
+0.6% +$475 0.01% 104
2024
Q2
$76.4K Buy
617
+3
+0.5% +$386 0.02% 99
2024
Q1
$81K Buy
614
+4
+0.7% +$493 0.02% 95
2023
Q4
$66.5K Buy
610
+5
+0.8% +$519 0.02% 104
2023
Q3
$62.3K Buy
605
+4
+0.7% +$431 0.02% 108
2023
Q2
$69.4K Buy
601
+401
+201% +$45.5K 0.02% 104
2023
Q1
$21.3K Buy
+200
New +$21.6K 0.01% 142

Other funds holding MRK

Gleason Group's MRK Position: Q2 2026 in Review

Gleason Group increased its Merck (MRK) stake by 29% in Q2 2026, buying an estimated $23.8K and bringing the position to 899 shares worth $116K. The position accounts for 0.01% of the portfolio, ranked #94.

Gleason Group first reported a position in MRK in Q1 2023 and has held it in 14 quarters since. 1,533 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Gleason Group held 899 shares of Merck worth $116K as of Q2 2026.
  • Gleason Group bought 203 Merck shares in Q2 2026, an estimated $23.8K.
  • Merck made up 0.01% of Gleason Group's portfolio in Q2 2026, its #94 holding.
  • Gleason Group first reported a position in Merck in Q1 2023 and has held it in 14 quarters since.
  • 1,533 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Gleason Group's 13F filing for Q2 2026, filed 13 Jul 2026.